Grove AI

News

Hippocratic AI has expanded with the acquisition of Grove AI, a specialist in AI used in pharma R&D, building on its patient-facing GenAI agents.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.